The stock of XBiotech Inc. (NASDAQ:XBIT) hit a new 52-week high and has $6.78 target or 5.00% above today’s $6.46 share price. The 8 months bullish chart indicates low risk for the $231.40 million company. The 1-year high was reported on Feb, 1 by Barchart.com. If the $6.78 price target is reached, the company will be worth $11.57M more. The stock decreased 2.12% or $0.14 during the last trading session, reaching $6.46. About 38,771 shares traded. XBiotech Inc. (NASDAQ:XBIT) has declined 7.38% since February 1, 2018 and is downtrending. It has underperformed by 7.38% the S&P500. Some Historical XBIT News: 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 20/04/2018 – DJ XBiotech Inc, Inst Holders, 1Q 2018 (XBIT); 02/04/2018 – XBIOTECH – WILL USE ITS TECHNOLOGY TO ADVANCE DEVELOPMENT OF TRUE HUMAN(TM )ANTI-NY-ESO-1 MONOCLONAL ANTIBODY, 12D7; 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis
LVMH MOET HENNESSY LOUIS VUITTON ORDINAR (OTCMKTS:LVMHF) had an increase of 1.51% in short interest. LVMHF’s SI was 147,800 shares in February as released by FINRA. Its up 1.51% from 145,600 shares previously. With 1,000 avg volume, 148 days are for LVMH MOET HENNESSY LOUIS VUITTON ORDINAR (OTCMKTS:LVMHF)’s short sellers to cover LVMHF’s short positions. The stock increased 2.07% or $6.65 during the last trading session, reaching $327.65. About 11 shares traded. LVMH MoÃ«t Hennessy Louis Vuitton S.E. (OTCMKTS:LVMHF) has 0.00% since February 1, 2018 and is . It has by 0.00% the S&P500.
More notable recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Nasdaq.com which released: “Dr. Eric Simpson to Present Bermekimab Results in Atopic Dermatitis at 2019 AAD Annual Meeting – Nasdaq” on January 29, 2019, also Seekingalpha.com with their article: “XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa – Seeking Alpha” published on January 23, 2019, Globenewswire.com published: “XBiotech Highlights Quarterly Developments Nasdaq:XBIT – GlobeNewswire” on August 10, 2018. More interesting news about XBiotech Inc. (NASDAQ:XBIT) were released by: Globenewswire.com and their article: “XBiotech Highlights Third Quarter Developments for 2018 Nasdaq:XBIT – GlobeNewswire” published on October 31, 2018 as well as Globenewswire.com‘s news article titled: “XBiotech Announces Successful Completion of GMP Audit – GlobeNewswire” with publication date: December 03, 2018.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company has market cap of $231.40 million. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It currently has negative earnings. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.